Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Face and Neck Atopic Dermatitis
NCT07873801Phase 3Not yet recruiting
- Sponsor
- Almirall
- Start
- Nov 2026
- Primary completion
- Feb 2028
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07873801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873801.